Not every pharma project requires a full-service agency
As pharmaceutical and biotech companies increase investment in scientific communication, many marketing and medical affairs teams face an important decision: should they partner with a large full-service healthcare agency or work with a specialist scientific content provider?
Both models offer value, but they solve very different problems. Choosing the wrong type of partner can lead to unnecessary complexity, inflated costs, and communication strategies that do not align with the organisation’s actual needs.
In many ways, paying for a full-service agency when the requirement is purely scientific content is similar to hiring an architect when what is really needed is a specialist builder.
What full-service healthcare agencies provide
Large integrated healthcare agencies such as Havas Lynx typically offer a broad range of services under one structure.
These may include:
- branding and creative strategy
- advertising campaigns
- public relations
- media buying and programmatic advertising
- CRM and digital marketing
- event management
- commercial launch support
For pharmaceutical companies preparing large-scale product launches or multi-channel commercial campaigns, this integrated model can be highly valuable. Full-service agencies are designed to coordinate multiple marketing disciplines across a single brand strategy.
However, this breadth of capability is not always necessary for every project.
When specialist scientific content partners make more sense
Many pharma and biotech organisations are not looking for a large advertising ecosystem. Instead, they need high-quality scientific communication delivered with speed, accuracy, and subject-matter expertise.
This is where specialist content partners become increasingly valuable.
Scientific communication projects often require:
- deep therapeutic understanding
- expert medical writing
- publication development
- healthcare professional education content
- regulatory awareness
- complex scientific storytelling
In these situations, organisations may benefit more from partnering with specialist providers focused specifically on scientific and medical content creation rather than broad commercial marketing execution.
The growing demand for content expertise
One of the biggest industry shifts in 2026 is the sheer volume of scientific content pharmaceutical companies must now produce. Medical affairs and communication teams are expected to deliver:
- publications
- congress materials
- educational articles
- digital scientific content
- omnichannel HCP engagement assets
This demand has increased the importance of scalable, expert-led content workflows. Companies increasingly need partners that can produce scientifically credible material efficiently while maintaining consistency across channels.
For many organisations, the challenge is no longer advertising reach it is scientific content quality and operational scale.
Choosing the right partner for the right objective
Ultimately, the decision depends on the organisation’s goals.
If the requirement involves large integrated campaigns, commercial branding, and broad media execution, a full-service agency may be the right fit.
However, if the priority is scientifically rigorous content creation, medical educationrt, medical education, or scalable expert-led communication, a specialist content partner may provide greater focus and efficiency may provide greater focus and efficiency.
At SciencePOD, this specialist approach reflects the growing need for scientifically credible, scalable content solutions within the pharmaceutical industry. By focusing deeply on scientific communication rather than broad advertising services, SciencePOD aligns with organisations seeking expert-led content tailored specifically for healthcare and life sciences audiences.